Levels of α-synuclein monomer and its oligomeric, aggregated and phosphorylated forms are well known to change in Parkinson’s Disease. An excellent review by Parnetti et al.(2019), published in Lancet Neurology, discusses the Biomarker potential of α-synuclein isoforms and their clinical utility.
Biosensis is addressing the need for reliable and accurate quantification of α-synuclein by releasing its NEWRapidTM ELISA Kit for this important target (BEK-2216). It represents the first assay in Biosensis’ collection of α-synuclein ELISA kits, with more kits in development!
Our new α-synuclein RapidTM ELISA Kit features:
·Real validation data on accurate quantification in human blood and CSF